GILD vs BIIB
GILD and BIIB side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | BIIBBIOGEN INC. |
|---|---|---|
| Market cap | $212.04B | $37.49B |
| P/E (TTM) | 25.2 | 109.8 |
| P/B | 16.26 | 2.53 |
| P/S | 7.2x | 3.8x |
| Dividend yield | 1.89% | — |
| Revenue | $30.99B(TTM) | $10.30B(TTM) |
| Revenue growth (YoY) | 2.4% | 2.2% |
| Net income | -$3.86B(TTM) | $347.60M(TTM) |
| Earnings growth (YoY) | 1672.9% | -20.8% |
| EPS, diluted | $-3.13(TTM) | $2.31(TTM) |
| EBIT margin | 34.0% | 28.7% |
| ROE | 65.3% | 8.7% |
| ROIC | 25.7% | 12.3% |
| Piotroski F | — | 3/9 |
| 1y total return | +47.1% | +69.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs BIIB
| Metric | GILD | BIIB |
|---|---|---|
| End value | $29.7K | $10.6K |
| Total return | +197.3% | +6.2% |
| CAGR | +11.1% | +0.6% |
| Volatility | 25.6% | 41.1% |
| Sharpe | 0.38 | 0.11 |
| Sortino | 0.56 | 0.18 |
| Max drawdown | -30.5% | -72.7% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)